NCT04568590

Brief Summary

Subjects enrolled in this study are eligible for the seasonal influenza vaccine. The purpose of this research study is to figure out if increasing individuals' awareness of the benefits of herd immunity, specifically to the local pediatric oncology community, can improve vaccination uptake rates.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
510

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 29, 2020

Completed
20 days until next milestone

Study Start

First participant enrolled

October 19, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 26, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 26, 2021

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

August 12, 2024

Completed
Last Updated

August 12, 2024

Status Verified

July 1, 2022

Enrollment Period

1 year

First QC Date

September 17, 2020

Results QC Date

October 13, 2022

Last Update Submit

March 7, 2024

Conditions

Keywords

altruismvaccine acceptanceflu vaccine

Outcome Measures

Primary Outcomes (3)

  • Change in Vaccine Hesitancy Scores Pre- and Post-Intervention.

    8-item Vaccine Hesitancy Scale. Subjects identified as vaccine-hesitant based on a Vaccine Hesitancy Score \>/= 3. Score range is 1-5 and \> or = 3 is considered vaccine hesitant.

    Baseline (Pre-intervention) and Post-Intervention, up to 4 hours

  • Pre-Intervention Vaccine Hesitancy Score

    8-item Vaccine Hesitancy Scale. Subjects identified as vaccine-hesitant based on a Vaccine Hesitancy Score \>/= 3. Score range is 1-5 and \> or = 3 is considered vaccine hesitant.

    baseline

  • Post-Intervention Vaccine Hesitancy Score

    8-item Vaccine Hesitancy Scale. Subjects identified as vaccine-hesitant based on a Vaccine Hesitancy Score \>/= 3. Score range is 1-5 and \> or = 3 is considered vaccine hesitant.

    Post-Intervention up to 4 Hours

Secondary Outcomes (2)

  • Rate of Influenza Vaccine Uptake

    baseline

  • Pre-Intervention Altruism Scale

    baseline

Other Outcomes (1)

  • Complex Interaction Interviews

    Month 9

Study Arms (1)

Vaccine Hesitant

EXPERIMENTAL

Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.

Behavioral: educational intervention

Interventions

If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.

Vaccine Hesitant

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All legal guardians of children aged 6 months and up who are influenza vaccine-eligible and present to the pediatric clinic.

You may not qualify if:

  • Legal guardians of children who are not influenza vaccine-eligible including children less than 6 months of age, children on immunosuppressive medications, and children with underlying medical conditions resulting in an immunocompromised state.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest Univesity Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location

Related Publications (1)

  • Marlowe E, Pranikoff S, Borsheim B, Salafian K, Halvorson EE, Kram DE. Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates. Vaccine. 2022 Nov 2;40(46):6625-6630. doi: 10.1016/j.vaccine.2022.09.074. Epub 2022 Oct 6.

MeSH Terms

Conditions

Vaccination RefusalAltruismInfluenza, Human

Interventions

Early Intervention, Educational

Condition Hierarchy (Ancestors)

Treatment RefusalTreatment Adherence and ComplianceHealth BehaviorBehaviorSocial BehaviorRespiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Child Health ServicesCommunity Health ServicesHealth ServicesHealth Care Facilities Workforce and ServicesPreventive Health Services

Results Point of Contact

Title
Elizabeth Halvorson, MD, MS
Organization
Wake Forest University School of Medicine

Study Officials

  • Elizabeth Halvorson, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2020

First Posted

September 29, 2020

Study Start

October 19, 2020

Primary Completion

October 26, 2021

Study Completion

October 26, 2021

Last Updated

August 12, 2024

Results First Posted

August 12, 2024

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification, will be available. The Study Protocol, Statistical Analysis Plan, and Informed Consent Form will also be available. All data will be available beginning 9 months and ending 36 months following article publication. The study team intends to share with researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
All data will be available beginning 9 months and ending 36 months following article publication.
Access Criteria
Please contact PI to request access to data beginning 9 months and ending 36 months after article publication.

Locations